ArticleJournal of oncology2012
PET Tracers for Clinical Imaging of Breast Cancer.
Article in Journal of oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.Frontiers in medicine · 2022Pooled it
- Characterization of accurate 3D collimator-detector response function for single- and multi-lofthole collimated SPECT cameras.Japanese journal of radiology · 2024Article
- The Role of Molecular Imaging in Personalized Medicine.Journal of personalized medicine · 2023Review
- Breast PET/MRI Hybrid Imaging and Targeted Tracers.Journal of magnetic resonance imaging : JMRI · 2023Review
- What's in a node? The clinical and radiologic significance of Virchow's node.Abdominal radiology (New York) · 2022Review
- Sugar alcohol provides imaging contrast in cancer detection.Scientific reports · 2019Article
- Feasibility study of a point-of-care positron emission tomography system with interactive imaging capability.Medical physics · 2019Article
- Integrated landscape of copy number variation and RNA expression associated with nodal metastasis in invasive ductal breast carcinoma.Oncotarget · 2018Article
- Discovery of hapten-specific scFv from a phage display library and applications for HER2-positive tumor imaging.Bioconjugate chemistry · 2014Article
- [Molecular breast imaging. An update].Der Radiologe · 2014Article
- Molecular imaging of breast cancer: present and future directions.Frontiers in chemistry · 2014Review
- Molecular imaging probes for diagnosis and therapy evaluation of breast cancer.International journal of biomedical imaging · 2013Article
- The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors.Journal of drug delivery · 2013Article
- Multi-Functionality in Theranostic Nanoparticles: is more Always Better?Journal of nanomedicine & nanotechnology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular imaging of breast cancer has undoubtedly permitted a substantial development of the overall diagnostic accuracy of this malignancy in the last years. Accurate tumour staging, design of individually suited therapies, response evaluation, early detection of recurrence and distant lesions have also evolved in parallel with the development of novel molecular imaging approaches. In this context, positron emission tomography (PET) can be probably seen as the most interesting molecular imaging technology with straightforward clinical application for such purposes. Dozens of radiotracers for PET imaging of breast cancer have been tested in laboratory animals. However, in this review we shall focus mainly in the smaller group of PET radiopharmaceuticals that have lead through into the clinical setting. PET imaging can be used to target general metabolic phenomena related to tumoural transformation, including glucose metabolism and cell proliferation, but can also be directed to specific hormone receptors that are characteristic of the breast cancer cell. Many other receptors and transport molecules present in the tumour cells could also be of interest for imaging. Furthermore, molecules related with the tumour microenvironment, tumour induced angiogenesis or even hypoxia could also be used as molecular biomarkers for breast cancer imaging.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.